Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies.

ABSTRACT: Novel immunotherapies continue to be developed and tested for application against a plethora of diseases. The clinical translation of immunotherapies requires an understanding of their mechanisms. The contributions of antibodies in driving long-term responses following immunotherapies continue to be revealed given their diverse effector functions. Developing an in-depth understanding of the role of antibodies in treatment efficacy is required to optimize immunotherapies and improve the chance of successfully translating them into the clinic. However, analyses of antibody responses can be challenging in the context of antigen-agnostic immunotherapies, particularly in the context of cancers that lack pre-defined target antigens. As such, robust methods are needed to evaluate the capacity of

SUBMITTER: Minott JA 

PROVIDER: S-EPMC9708883 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature